Edwards Lifesciences’ RESILIA data may shift the valve debate, but not without caveats
Valve durability is becoming a lifetime-care question. Edwards Lifesciences’ 10-year RESILIA data raise the stakes for heart teams.
Why Edwards Lifesciences is betting on transcatheter replacement to solve tricuspid regurgitation
Find out how transcatheter tricuspid valve replacement is reshaping treatment options for severe regurgitation and what clinicians are watching next.
Can Trisol’s TTVR platform solve the right heart puzzle in tricuspid regurgitation care?
Trisol’s valve shows early safety and efficacy in high-risk TR patients. Explore what this means for the future of transcatheter tricuspid therapies.